Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: E7080 Clear all
Completed Phase 2 Interventional Results available

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT02973997
View directory record Official record
Conditions
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Follicular Carcinoma, Recurrent Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Follicular Carcinoma AJCC v7, Stage III Thyroid Gland Papillary Carcinoma AJCC v7, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Other · Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT02702388
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Lenvatinib matching placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

NCT01525394
View directory record Official record
Conditions
Refractory Solid Tumors, Lymphomas
Interventions
Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

NCT03477175
View directory record Official record
Conditions
Solid Tumors
Interventions
E7080, Comparator Drug, Comparator Drug: Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

NCT04039607
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Ipilimumab, Sorafenib, lenvatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
15
States / cities
Tucson, Arizona • Coronado, California • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

NCT03564691
View directory record Official record
Conditions
Neoplasms
Interventions
MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Eribulin and Lenvatinib in Advanced Solid Tumors

NCT02640508
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Eribulin, Lenvatinib
Drug
Lead sponsor
Virginia G. Kaklamani
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

NCT02199379
View directory record Official record
Conditions
Renal Impairment, Disease Severity
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 23, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

NCT04171622
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Completed No phase listed Observational

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

NCT05579847
View directory record Official record
Conditions
Renal Cell Carcinoma Stage IV
Interventions
mHealth Smart Phone Application, eHEALS digital literacy test, Weekly Quiz, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Patient Post Intervention Survey
Other · Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

NCT02686164
View directory record Official record
Conditions
Tumors
Interventions
Lenvatinib, Midazolam
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Detroit, Michigan • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 23, 2026, 10:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

NCT04626479
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151
View directory record Official record
Conditions
Recurrent and Refractory Solid Tumors
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

NCT01136967
View directory record Official record
Conditions
Unresectable Stage III, Stage IV Melanoma
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 23, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04781088
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Lenvatinib, Paclitaxel, Pembrolizumab
Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

NCT05064280
View directory record Official record
Conditions
Brain Metastases, Tumor
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

NCT03506048
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Lenvatinib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 23, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab, MK-4830, Boserolimab, Lenvatinib, Etoposide, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

NCT04154189
View directory record Official record
Conditions
Osteosarcoma
Interventions
Lenvatinib, Ifosfamide, Etoposide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 23, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

NCT06036836
View directory record Official record
Conditions
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions
favezelimab/pembrolizumab, pembrolizumab, lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 23, 2026, 10:08 PM EDT